Men's Health News

RSS

High anxiety can turn good dads bad

Normally, male California mice are surprisingly doting fathers, but new research published in the journal Physiological and Biochemical Zoology suggests that high anxiety can turn these good dads bad.

14 Jun 2012

Long-lasting weekly fertility injections work as well as daily

New long-lasting weekly injections of fertility hormones are as safe and effective as standard daily injections, according to Cochrane researchers. The researchers compared weekly and daily hormone injections in a Cochrane systematic review and found no difference in pregnancies or serious side effects between the two regimens.

13 Jun 2012

Another benefit of CPAP therapy for men with OSA

Men who suffer from obstructive sleep apnea (OSA) are seeing another potential benefit from continuous positive airway pressure therapy, or CPAP: improved sexual function and satisfaction in non-diabetic men under age 60.

13 Jun 2012

African-American survivors of prostate cancer have unmet psychosocial needs

Researchers at Moffitt Cancer Center have found that in African-American families where men are diagnosed with prostate cancer, they have unmet psychosocial needs that affect their survivorship, as well as family and social relationships.

12 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

Vitamin D deficiency may be an important risk factor for erectile dysfunction

A paper just published hypothesizes that vitamin D deficiency may be an important risk factor for erectile dysfunction (ED).

7 Jun 2012

Strong link between high levels of stress and dramatic weight gain among U.S. males

A new survey by Aviva USA, in collaboration with Mayo Clinic, finds the primary factor contributing to stress for men is their financial situation. The survey also reveals a strong correlation between high levels of stress and dramatic weight gain among U.S. males.

6 Jun 2012

Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC

Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.

6 Jun 2012

Brains of anxious girls work much harder than those of boys

In a discovery that could help in the identification and treatment of anxiety disorders, Michigan State University scientists say the brains of anxious girls work much harder than those of boys.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Women more likely to develop a disability than men

According to a new study released by The State Farm Center for Women and Financial Services at The American College, women – whether they're working or a stay-at-home mom, single or married – women are most at risk both physically and financially when it comes to disability.

5 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.

5 Jun 2012

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO

New data presented this weekend at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy.

2 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Liver metastases predicts shorter overall survival in men with mCRPC

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2012

Moderately higher risk of stroke for women than men with irregular heart rhythm

Women with irregular heart rhythm (known as atrial fibrillation) have a moderately increased risk of stroke compared with men, suggesting that female sex should be considered when making decisions about anti-clotting treatment, finds a study published on bmj.com today.

1 Jun 2012

Large-scale, coordinated effort needed to stop increase in HIV transmission among MSM in China

HIV transmission in China is increasing faster among men who have sex with men (MSM) than in any other population, a trend that "cannot continue," a group of researchers working in China write in a Nature commentary, adding, "Policymakers, public health researchers, clinicians, educators, community leaders and other stakeholders in China must come together to educate everyone, and gay men in particular, about HIV prevention and treatment -- before any more people become infected as a result of ignorance and fear."

1 Jun 2012